The US FDA has granted accelerated approval for the use of this CD30 monoclonal antibody in treating relapsed or refractory Hodgkin's lymphoma and anaplastic large cell lymphoma.329. The gene discussed is TNFRSF8; the disease is Hodgkins lymphoma.